Results 211 to 220 of about 323,198 (362)

Community Pharmacists' Perspectives on Antibiotic Misuse and Antimicrobial Resistance in Cyprus: A Reflexive Thematic Analysis. [PDF]

Antibiotics (Basel)
Sullman MJM, Lajunen TJ.
europepmc   +1 more source

Retrospective Assessment of the Clinical Pharmacist Sheets among a Few Iraqi General Hospitals

, 2021
Manal Khalid Abdulridha
openalex   +2 more sources

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Community pharmacists preparedness to control OTC medication abuse in Saudi Arabia: a nationwide cross-sectional survey-based study. [PDF]

Front Public Health
Alsheikh MY, Fathelrahman AI.
europepmc   +1 more source

2247 Clinical pharmacists working in primary care supporting people living with dementia: a UK survey [PDF]

Victoria Vickerstaff, Alice Burnand, Alistair Woodward, LAURA ALMEIDA MELO, J Manthorpe, Yogini Jani, Mine Orlu, Cini Bhanu, K Samsi, Jane Wilcock, Greta Rait, Neil M Davies   +11 more
openalex   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Cultural and systemic determinants of medication adherence management: mixed-methods evidence from Jordanian healthcare professionals. [PDF]

Front Public Health
Abed A, Abu Assab M, Zakaraya Z, Abu Dayyih W, Alotaibi BS, Alsubaie N.   +5 more
europepmc   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Integrating Large Language Models Into UAE Community Pharmacies: Pharmacists' Perspectives on Benefits, Concerns, and Implementation Barriers. [PDF]

Int J Telemed Appl
Jarab AS, Al Meslamani AZ, Al-Qerem W, Alyafeai H, Al Hamarneh YN, Eberhardt J.   +5 more
europepmc   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source